These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 22983310)

  • 1. Placebo? no thanks, it might be bad for me!
    Garattini S; Bertelé V; Banzi R
    Eur J Clin Pharmacol; 2013 Mar; 69(3):711-4. PubMed ID: 22983310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.
    Goldberg LD; Edwards NC; Fincher C; Doan QV; Al-Sabbagh A; Meletiche DM
    J Manag Care Pharm; 2009 Sep; 15(7):543-55. PubMed ID: 19739877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lessons from randomised direct comparative trials.
    Achiron A; Fredrikson S
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S19-24. PubMed ID: 19200860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.
    Johnston J; So TY
    Drugs; 2012 Jun; 72(9):1195-211. PubMed ID: 22642799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon beta and glatiramer acetate therapy.
    McGraw CA; Lublin FD
    Neurotherapeutics; 2013 Jan; 10(1):2-18. PubMed ID: 23264098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The technology of treatment of multiple sclerosis with long-term immunomodulating drugs (disease modifying drugs--DMD)--beta-interferons and glatiramer-acetate].
    Federal service on surveillance in healthcare and social development (Roszdravnadzor)
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):86-92. PubMed ID: 21916162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease-modifying agents in the treatment of multiple sclerosis: a review of long-term outcomes.
    Katrych O; Simone TM; Azad S; Mousa SA
    CNS Neurol Disord Drug Targets; 2009 Dec; 8(6):512-9. PubMed ID: 19811446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod.
    Roskell NS; Zimovetz EA; Rycroft CE; Eckert BJ; Tyas DA
    Curr Med Res Opin; 2012 May; 28(5):767-80. PubMed ID: 22462530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis.
    Simpson D; Noble S; Perry C
    CNS Drugs; 2002; 16(12):825-50. PubMed ID: 12421116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spotlight on glatiramer acetate in relapsing-remitting multiple sclerosis.
    Simpson D; Noble S; Perry C
    BioDrugs; 2003; 17(3):207-10. PubMed ID: 12749757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
    Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
    Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Long-term effects of glatiramer acetate in multiple sclerosis].
    Brochet B
    Rev Neurol (Paris); 2008 Nov; 164(11):917-26. PubMed ID: 18790510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Teriflunomide for multiple sclerosis.
    He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L
    Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center.
    Wolinsky JS; Narayana PA; Johnson KP;
    Mult Scler; 2001 Feb; 7(1):33-41. PubMed ID: 11321192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.
    He A; Spelman T; Jokubaitis V; Havrdova E; Horakova D; Trojano M; Lugaresi A; Izquierdo G; Grammond P; Duquette P; Girard M; Pucci E; Iuliano G; Alroughani R; Oreja-Guevara C; Fernandez-Bolaños R; Grand'Maison F; Sola P; Spitaleri D; Granella F; Terzi M; Lechner-Scott J; Van Pesch V; Hupperts R; Sánchez-Menoyo JL; Hodgkinson S; Rozsa C; Verheul F; Butzkueven H; Kalincik T;
    JAMA Neurol; 2015 Apr; 72(4):405-13. PubMed ID: 25665031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis.
    Carter NJ; Keating GM
    Drugs; 2010 Aug; 70(12):1545-77. PubMed ID: 20687620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of interferon Beta and glatiramer acetate in multiple sclerosis.
    Goodin DS
    Semin Neurol; 2013 Feb; 33(1):13-25. PubMed ID: 23709209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.